For the Quarter Ending September 2025
APAC
• In China, the Escitalopram Oxalate Price Index fell in Q3 2025, influenced by a -2.3% year-on-year decline in producer prices.
• Production costs showed mixed trends, with naphtha feedstock firming and natural gas prices rising in Q3 2025.
• Demand for Escitalopram Oxalate was supported by rising chronic disease treatments and bolstered psychiatric care.
• The Manufacturing Index was Contracting in September 2025, while industrial production expanded by 6.5% year-on-year.
• Retail sales increased by 3.0% year-on-year in September 2025, despite a -0.3% year-on-year CPI decrease.
• The unemployment rate was 5.2% in September 2025, suggesting some economic pressure on consumers.
• Domestic inventories remained comfortable in Q3 2025, with US tariffs expected to elevate API costs.
• Escitalopram Oxalate price forecast remains under pressure, reflecting bearish consumer confidence (89.6 in September 2025).
Why did the price of Escitalopram Oxalate change in September 2025 in APAC?
• Producer prices declined -2.3% year-on-year in September 2025, contributing to lower input costs.
• Naphtha feedstock costs firmed and natural gas prices rose in Q3 2025, increasing production expenses.
• Strong demand for chronic disease treatments was partially countered by contracting manufacturing activity.
Europe
• In Germany, the Escitalopram Oxalate Price Index fell in Q3 2025, influenced by declining industrial production.
• Escitalopram Oxalate production costs faced mixed pressures, with producer prices falling 1.7% in September 2025.
• Demand was constrained by Germany's stagnating economic activity and industrial production declining 1.0% in September 2025.
• The Escitalopram Oxalate Price Index is forecast to remain stable due to market overcapacity in Q3 2025.
• Germany's Manufacturing Index was contracting in Q3 2025, reflecting a broader economic slowdown.
• European natural gas prices declined year-on-year in Q3 2025, easing some Escitalopram Oxalate production costs.
• Overcapacity in the European chemical industry and declining German exports impacted Escitalopram Oxalate trade.
• Consumer Price Index rose 2.4% in September 2025, increasing general manufacturing and distribution costs.
Why did the price of Escitalopram Oxalate change in September 2025 in Europe?
• Producer prices fell 1.7% in September 2025, reducing Escitalopram Oxalate manufacturing costs.
• Germany's Manufacturing Index contracted in Q3 2025, signaling weaker industrial demand.
• European chemical overcapacity and declining German exports pressured Escitalopram Oxalate prices.
North America
• In the United States, Escitalopram Oxalate Price Index rose in Q3 2025, driven by robust demand and rising costs.
• Price Forecast suggests continued upward pressure from sustained healthcare spending and increasing input expenses.
• Production costs increased, influenced by a 2.6% PPI rise in August 2025 and higher natural gas feedstock.
• Demand outlook remained strong, supported by 5.42% retail sales increase and 4.3% unemployment in September 2025.
• General inflation, with CPI up 3.0% year-over-year in September 2025, impacted operational costs.
• Biopharma industry momentum gathered in Q3 2025, with new US FDA drug approvals boosting demand.
• Trade flows faced disruption from tariff uncertainty in Q3 2025; US chemical exports and imports softened.
• Industrial production increased 0.1% year-on-year in September 2025, indicating stable manufacturing activity.
• Consumer confidence declined to 94.2 in September 2025, potentially affecting patient treatment seeking.
Why did the price of Escitalopram Oxalate change in September 2025 in North America?
• Rising production costs, with PPI up 2.6% in August 2025, directly impacted manufacturing expenses.
• Strong consumer spending, retail sales up 5.42% in September 2025, bolstered patient access and demand.
• General inflation, CPI rising 3.0% in September 2025, contributed to higher operational and raw material costs.
